Emerging analyses show that women using GLP-1 receptor agonists such as semaglutide, liraglutide, and tirzepatide report more adverse events than men, including neurologic and psychiatric symptoms. These differences may stem from higher drug concentrations in women, yet sex-specific data remain scarce in clinical trials.
Study Details:
GLP-1 receptor agon…
